Trastuzumab

About

Therapy type: Targeted therapy

Therapy strategy: HER2 inhibition

Mappings

NCI Thesaurus: Trastuzumab (coding:ncit:C1647)

RxNorm: trastuzumab (coding:rxcui:224905, coding:omop:1387104)

View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this therapy.

Organizations
Biomarkers
Cancer types
Therapies
Organizations Biomarkers Cancer types Therapies
FDA (2) HC (1) HER2-positive, PD-L1 (CPS) >= 1 Adenocarcinoma of the Gastroesophageal Junction Cisplatin, Fluorouracil, Pembrolizumab, Trastuzumab
FDA (2) HER2-positive, PD-L1 (CPS) >= 1 Adenocarcinoma of the Gastroesophageal Junction Capecitabine, Oxaliplatin, Pembrolizumab, Trastuzumab
FDA (4) HC (5) HER2-positive Invasive Breast Carcinoma Docetaxel, Pertuzumab, Trastuzumab
FDA (8) HC (2) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Doxorubicin, Paclitaxel, Pertuzumab, Trastuzumab
FDA (8) HC (2) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Docetaxel, Epirubicin, Fluorouracil, Pertuzumab, Trastuzumab
FDA (4) HC (2) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Epirubicin, Fluorouracil, Paclitaxel, Pertuzumab, Trastuzumab
FDA (4) HC (2) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Docetaxel, Doxorubicin, Fluorouracil, Pertuzumab, Trastuzumab
FDA (4) HC (2) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Doxorubicin, Fluorouracil, Paclitaxel, Pertuzumab, Trastuzumab
FDA (4) HC (2) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Docetaxel, Epirubicin, Pertuzumab, Trastuzumab
FDA (4) HC (2) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Epirubicin, Paclitaxel, Pertuzumab, Trastuzumab
FDA (4) HC (2) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Docetaxel, Doxorubicin, Pertuzumab, Trastuzumab
FDA (4) HC (2) HER2-positive Invasive Breast Carcinoma Carboplatin, Docetaxel, Pertuzumab, Trastuzumab
FDA (2) HC (2) HER2-positive Invasive Breast Carcinoma Trastuzumab
FDA (2) HER2-positive Adenocarcinoma of the Gastroesophageal Junction Trastuzumab
FDA (2) HC (1) HER2-positive Invasive Breast Carcinoma Capecitabine, Trastuzumab, Tucatinib
HC (1) HER2-positive Invasive Breast Carcinoma Carboplatin, Docetaxel, Trastuzumab
HC (2) HER2-positive Invasive Breast Carcinoma Carboplatin, Paclitaxel, Pertuzumab, Trastuzumab
HC (2) HER2-positive Invasive Breast Carcinoma Paclitaxel, Pertuzumab, Trastuzumab
HC (2) HER2-positive Invasive Breast Carcinoma Pertuzumab, Trastuzumab, Vinorelbine
HC (1) HER2-positive Invasive Breast Carcinoma Docetaxel, Paclitaxel, Trastuzumab
FDA (2) HER2-positive, Wild type KRAS, Wild type NRAS Colorectal Adenocarcinoma Trastuzumab, Tucatinib
FDA (2) ER positive, HER2-positive Invasive Breast Carcinoma Anastrozole, Palbociclib, Trastuzumab
FDA (2) HER2-positive, PR positive Invasive Breast Carcinoma Anastrozole, Palbociclib, Trastuzumab
FDA (2) ER positive, HER2-positive Invasive Breast Carcinoma Anastrozole, Palbociclib, Pertuzumab, Trastuzumab
FDA (2) HER2-positive, PR positive Invasive Breast Carcinoma Anastrozole, Palbociclib, Pertuzumab, Trastuzumab
FDA (2) ER positive, HER2-positive Invasive Breast Carcinoma Exemestane, Palbociclib, Trastuzumab
FDA (2) HER2-positive, PR positive Invasive Breast Carcinoma Exemestane, Palbociclib, Trastuzumab
FDA (2) ER positive, HER2-positive Invasive Breast Carcinoma Exemestane, Palbociclib, Pertuzumab, Trastuzumab
FDA (2) HER2-positive, PR positive Invasive Breast Carcinoma Exemestane, Palbociclib, Pertuzumab, Trastuzumab
FDA (2) ER positive, HER2-positive Invasive Breast Carcinoma Fulvestrant, Palbociclib, Trastuzumab
FDA (2) HER2-positive, PR positive Invasive Breast Carcinoma Fulvestrant, Palbociclib, Trastuzumab
FDA (2) ER positive, HER2-positive Invasive Breast Carcinoma Fulvestrant, Palbociclib, Pertuzumab, Trastuzumab
FDA (2) HER2-positive, PR positive Invasive Breast Carcinoma Fulvestrant, Palbociclib, Pertuzumab, Trastuzumab
FDA (2) ER positive, HER2-positive Invasive Breast Carcinoma Letrozole, Palbociclib, Trastuzumab
FDA (2) HER2-positive, PR positive Invasive Breast Carcinoma Letrozole, Palbociclib, Trastuzumab
FDA (2) ER positive, HER2-positive Invasive Breast Carcinoma Letrozole, Palbociclib, Pertuzumab, Trastuzumab
FDA (2) HER2-positive, PR positive Invasive Breast Carcinoma Letrozole, Palbociclib, Pertuzumab, Trastuzumab
FDA (2) HER2-positive Invasive Breast Carcinoma Paclitaxel, Pertuzumab, Trastuzumab, Trastuzumab deruxtecan